Evaluation of the effect of Propolis on the recovery process of COVID 19 patients

Evaluation of the effect of Propolis in the treatment of COVID 19 patients

This clinical trial was performed on 72 patients, divided into two groups of 36, including a control group and parallel groups. This study is Double-blind and block randomization method is used.

The field of work is clinical - internal. This study is performed in the Tohid Hospital in Sanandaj. Patients, physicians, and nurses who evaluate the outcomes will be blind to the groups studied.

Inclusion Criteria: Confirmed diagnosis of COVID19 with RT-PCR, Hospitalized patients, Ventilator independent patients Exclusion Criteria: Pregnancy, Breastfeeding, Type 1 diabetes, Severe renal failure, Metabolic acidosis, Severe respiratory failure, Chemotherapy recipients, Taking anticoagulants

Patients in both groups receive the treatment based on the Covid-19 National Guidelines. Patients in the intervention group, in addition to the standard treatment protocol, receive Propolis Capsule in the form of 500mg capsules (made by Shahdineh Golha Company) twice a day for 14 days and the control group also receives placebo according to the above method.

Fever, Cough, Muscle pain, Blood oxygen saturation percentage, CRP, CBC, ESR, Respiratory Rate, Heart Rate, CT scan findings, Gastrointestinal symptoms, Anorexia, Loss of Smell and Taste, Shortness of breath, Headache, Sore throat, BMI, IL-6

Using block randomization method with a block size of 4. Sampling method at this study will be according to random allocation. Participants will enter the study according to inclusion criteria, and then will be divided into two groups according to randomization table. One group will receive Propolis Capsule and the other will receive placebo. The participants and administrator do not have any information about content of capsules (double blinded study). The list of randomization was computer-generated. supplements and placebo capsules were placed in completely identical packages and were coded by someone who was unaware of the nature of the study in numbered bottles based on the list. And another person who was unaware of the contents of the pack provided them to the patients.

All supplements and placebo capsules were identical with respect to appearance and only differed in coding of the capsules. The treatment code of the intervention supplements was blinded for subjects, investigators and staff involved in the conduct of the study.